170 related articles for article (PubMed ID: 29570686)
21. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
23. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
[TBL] [Abstract][Full Text] [Related]
24. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
[TBL] [Abstract][Full Text] [Related]
25. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
[TBL] [Abstract][Full Text] [Related]
26. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
27. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Bose A; Lowe DB; Rao A; Storkus WJ
Melanoma Res; 2012 Jun; 22(3):236-43. PubMed ID: 22504156
[TBL] [Abstract][Full Text] [Related]
28. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
[TBL] [Abstract][Full Text] [Related]
29. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
30. Novel pyrazole and indazole derivatives: synthesis and evaluation of their anti-proliferative and anti-angiogenic activities.
Tzanetou E; Liekens S; Kasiotis KM; Fokialakis N; Haroutounian SA
Arch Pharm (Weinheim); 2012 Oct; 345(10):804-11. PubMed ID: 22707414
[TBL] [Abstract][Full Text] [Related]
31. Axitinib (Inlyta) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928
[No Abstract] [Full Text] [Related]
32. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
[TBL] [Abstract][Full Text] [Related]
33. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.
Schindler E; Amantea MA; Karlsson MO; Friberg LE
CPT Pharmacometrics Syst Pharmacol; 2017 Jun; 6(6):373-382. PubMed ID: 28378918
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
35. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
37. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.
Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A
Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study.
El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA
Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
40. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]